Careers  |  Sign In  |  Register  |   Twitter

Mepolizumab Fails in a Phase II Trial

Fails to alleviate moderate persistent asthma symptoms

Mepolizumab, an IL-5 inhibitor, failed to alleviate moderate persistent asthma symptoms in a phase II trial of patients resistant to corticosteroids.

References and Resources
Flood-Page P, Swenson C, Faiferman I. A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma. American Journal of Respiratory and Critical Care Medicine. 2007. Vol 176; pp. 1062-1071.

Click Here to view abstract.

Sponsored by The Doctor’s Channel